



Mechanism of interactions between α -conotoxin RegIIA and carbohydrates at the human $\alpha 3\beta 4$ nicotinic acetylcholine receptor

Meiling Zheng^{1,2,4} · Han-Shen Tae³ · Liang Xue^{1,2} · Tao Jiang^{1,2} · Riley Yu^{1,2,4}

Received: 15 February 2021 / Accepted: 23 May 2021 / Published online: 22 July 2021
© The Author(s) 2021

Abstract

Conotoxins are marine peptide toxins from marine cone snails. The α -conotoxin RegIIA can selectively act on human (h) $\alpha 3\beta 4$ nicotinic acetylcholine receptor (nAChR), and is an important lead for drug development. The high-resolution cryo-electron microscopy structure of the $\alpha 3\beta 4$ nAChR demonstrates several carbohydrates are located near the orthosteric binding sites, which may affect α -conotoxin binding. Oligosaccharide chains can modify the physical and chemical properties of proteins by changing the conformation, hydrophobicity, quality and size of the protein. The purpose of this study is to explore the effect of oligosaccharide chains on the binding modes and activities of RegIIA and its derivatives at $\alpha 3\beta 4$ nAChRs. Through computational simulations, we designed and synthesized RegIIA mutants at position 14 to explore the importance of residue H14 to the activity of the peptide. Molecular dynamics simulations suggest that the oligosaccharide chains affect the binding of RegIIA at the $\alpha 3\beta 4$ nAChR through direct interactions with H14 and by affecting the C-loop conformation of the binding sites. Electrophysiology studies on H14 analogues suggest that in addition to forming direct interactions with the carbohydrates, the residue might play an important role in maintaining the conformation of the peptide. Overall, this study further clarifies the structure–activity relationship of α -conotoxin RegIIA at the $\alpha 3\beta 4$ nAChR and, also provides important experimental and theoretical basis for the development of new peptide drugs.

Keywords Oligosaccharide chains · nAChR · Conotoxin · Action mechanism

Edited by Chengchao Chen.

Meiling Zheng and Han-Shen Tae contributed equally to this work

✉ Riley Yu
ryu@ouc.edu.cn

- ¹ Molecular Synthesis Center & Key Laboratory of Marine Drugs, Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, Qingdao 266003, China
- ² Innovation Platform of Marine Drug Screening & Evaluation, Pilot National Laboratory for Marine Science and Technology (Qingdao), Qingdao 266100, China
- ³ Illawarra Health and Medical Research Institute (IHMRI), University of Wollongong, Wollongong, NSW 2522, Australia
- ⁴ Laboratory for Marine Drugs and Bioproducts, Pilot National Laboratory for Marine Science and Technology (Qingdao), Qingdao 266003, China

Introduction

Conotoxins are marine peptide toxins isolated from the venom of cone snails which are used for prey capture and/or predator defense. Based on the conservation of their genes and their precursor protein signal peptides, they can be divided into A, M, P, O, S, T and other superfamilies (Robinson and Norton 2014). Conotoxins are processed from precursor peptides containing 70–120 amino acid residues (Olivera 2006) and, mature peptides generally contain 12–13 amino acids and multiple pairs of disulfide bonds. Among them, the α -conotoxins (α -Ctxs) are selective antagonists for various nicotinic acetylcholine receptor (nAChR) subtypes (Azam and McIntosh 2009; Olivera et al. 2008). The α -Ctxs are a family of small peptides rich in disulfide bonds, which are composed of 12–20 amino acids. The α -Ctxs are divided in two loops (m and n) with the number of residues in each loop is used to categorize them into several structural subgroups (m/n) and the loop size roughly correlates with the pharmacological target selectivity (Lebbe et al. 2014).

The nAChRs are ligand-gated ion channels that contain functional cysteine loops in their sequence and belong to the cys-loop receptor family (Taly et al. 2009). This family of receptors is derived from a common gene and, other members include the serotonin (5-HT₃), γ -aminobutyric acid type A (GABA_A) and glycine receptors (Changeux 2012). The nAChRs are pentameric transmembrane proteins composed of five subunits and, in vertebrates there are at least 17 nAChR subunits including $\alpha 1$ – $\alpha 10$, $\beta 1$ – $\beta 4$, γ , δ and ϵ (Gotti et al. 2007). Different subunits aggregate to form nAChR subtypes with different functions (Gotti and Clementi 2004). The receptor consists of an extracellular domain (ECD), a transmembrane domain (TMD) and an intracellular domain (ICD). The ECD of two adjacent subunits contributes to the ligand binding site, consisting of loops A, B, and C of the principal subunit and the β -sheet of the complementary subunit.

The nAChRs are divided into two categories: muscle and neuronal types. The $\alpha 3\beta 4$ nAChRs are mainly expressed on the sensory and autonomic nerve central cells of the peripheral nervous system, and on the neurons of the central nervous system (Sharma 2013). Studies have suggested the $\alpha 3\beta 4$ subtype does not only mediate nicotine withdrawal, but it also reduces self-administration of many drugs of abuse (Glick et al. 2008; Jackson et al. 2013, 2015). In addition, $\alpha 3\beta 4$ nAChRs are overexpressed in tumor cells and play a role in promoting carcinogenesis upon binding of ligands (i.e., nicotine) (Yi et al. 2012). Therefore, the discovery of high-efficiency and low-toxicity $\alpha 3\beta 4$ nAChR inhibitors could be developed as lead compounds for the treatment of these major diseases (Posadas et al. 2013; Qian et al. 2019).

RegIIA is a 4/7- α -Ctx isolated from the venom of *Conus regius*, and potently inhibits the human $\alpha 3\beta 2$, $\alpha 3\beta 4$ and $\alpha 7$ nAChRs (Franco et al. 2012) with IC₅₀ of 130, 50 and 210 nmol/L, respectively (Cuny et al. 2016). RegIIA is more potent at murine $\alpha 3\beta 2$ than human $\alpha 3\beta 2$, but the potency of RegIIA at the $\alpha 3\beta 4$ subtype of the two species is similar. Previous studies have confirmed that Glu98 of the murine $\alpha 3$ subunit (Pro at the human $\alpha 3$ subunit) is mainly responsible for the species potency gap (Kompella et al. 2015a). Through rational design of analogues, [N11A, N12A] RegIIA has 27-fold improved selectivity for $\alpha 3\beta 4$ subtype than $\alpha 3\beta 2$, despite sevenfold loss of potency compared to the parent peptide (Kompella et al. 2015b).

In 2019, Gharpure et al. successfully resolved the first structure of $\alpha 3\beta 4$ nAChR bound with nicotine through cryo-electron microscopy, with a resolution of 3.34 Å (Fig. 1A) (Gharpure et al. 2019). A large number of carbohydrates are observed at the apex of the ECD and near the orthosteric binding sites, and each carbohydrate is composed of two or three monosaccharides in a different order. The linear oligosaccharides near the orthosteric binding site are composed of two β -D-glucosamine and one β -D-mannose (Fig. 1B).

It is generally agreed that α -Ctxs are selective antagonists of nAChRs, and its site of action is located on the orthosteric binding site. Thus, we proposed that this linear oligosaccharide extends to the binding site of conotoxins, which may potentially affect conotoxin binding and its activity. In addition, the linear oligosaccharides are located close to the C-loop (Fig. 1B, C), thus they may also influence the receptor-conotoxin interaction by affecting the conformation of the loop. So far, influence of carbohydrates on conotoxin-nAChR dynamics is yet to be investigated. Therefore, in this study, computational simulations and two-electrode voltage clamp electrophysiology were used to explore whether carbohydrates on $\alpha 3\beta 4$ nAChRs can affect the interactions with RegIIA and its analogues. Our findings suggest the oligosaccharide chains not only facilitate the interaction of RegIIA residue H14 with the receptor, they also affect C-loop conformation. Additionally, electrophysiology results support direct interaction of residue H14 with the carbohydrates and it may also play a role in maintaining the conformation of RegIIA. This study contributes to understanding the structure–activity relationship of RegIIA at the $\alpha 3\beta 4$ nAChR, and assists in the design of novel drugs targeting the $\alpha 3\beta 4$ subtype.

Results and discussion


Synthesis of α -conotoxin RegIIA and its analogues

RegIIA and its analogues (Fig. 2) were synthesized by solid-phase Fmoc chemistry, as previously described (Yu et al. 2013). To achieve regioselective oxidation, Fmoc-Cys(Trt)-OH was used at Cys I and Cys III positions, and Fmoc-Cys(Acm)-OH was used at Cys II and Cys IV positions. The fully oxidized product was separated and purified by RP-HPLC (reversed-phased-high performance liquid chromatography). The molecular weight and purity were confirmed by electrospray ionization–mass spectrometry (ESI–MS) and analytical HPLC (Supplementary Fig. S1).

Molecular dynamics simulations of RegIIA at $\alpha 3\beta 4$ nAChRs.

We performed molecular dynamics (MD) simulations on the α -Ctx RegIIA and $\alpha 3\beta 4$ nAChR complex in the presence or absence of oligosaccharide chains. As the carbohydrates are located at the top of the receptor, only the $\alpha 3\beta 4$ nAChR ECD model was simulated. MD simulations suggested the interaction modes of RegIIA at apo- and carbohydrate-bound $\alpha 3\beta 4$ nAChRs were similar to the binding mode of RegIIA predicted in our previous studies (Fig. 3A, B, Table 1) (Cuny et al. 2016; Xu et al. 2020). In both models, RegIIA N9 and H5 residues formed hydrogen bonds with $\beta 4$ K161 and $\alpha 3$

Fig. 1 Structure of the human (h) $\alpha 3\beta 4$ nAChR (PDB ID: 6PV7). **A** Side view of the h $\alpha 3\beta 4$ nAChR bound with two nicotine (orange). **B** A magnified view of the orthosteric binding site (dashed frame). The silver white colored oligosaccharide chain is composed of two β -D-glucosamine (NAG) and one β -D-mannose (BMA), which are connected to the receptor asparagine residue 117 through N-glycosidic bonds. **C** Top view of the h $\alpha 3\beta 4$ nAChR. The $\alpha 3$ and $\beta 4$ subunits are colored purple and cyan, respectively



P198, while N11 formed direct interactions with $\alpha 3$ S150 and $\beta 4$ R83 (Fig. 3C–E, G, H).

One main difference between the two systems was the interaction between the oligosaccharide chain and $\beta 4$ N117 through N-glycosidic bonds. The presence of linear oligosaccharides mainly affected RegIIA N12 and H14, which involved hydrogen bond interactions between β -D-mannose and the two residues (Fig. 3B, F). The 250 ns-MD simulation also showed change of the distance between β -D-mannose and N12 and H14, (Fig. 4A, B, Supplementary Fig. S2) and although the contact was unstable, interactions with N12 was relatively more stable than H14. Overall, MD simulations indicated that the linear oligosaccharide at $\beta 4$ N117 positions was flexible and formed relatively weak interactions with residues at the solvent exposed surface of RegIIA.

We also found that the oligosaccharide chain linked to $\alpha 3$ N141 through N-glycosidic bonds can directly interact with $\alpha 3$ H186 (Fig. 5A, Supplementary Fig. S3). The average distance between the CA of $\alpha 3$ C193 and the CA of $\beta 4$ S40 on the C-loop in apo- and carbohydrate-bound models was about 18 Å and 20 Å, respectively (Fig. 5C). Similarly, the C-loop was also slightly more opened in the carbohydrate-free model than the carbohydrate-bound model (Supplementary Fig. S7). The more closed C-loop suggested that in the presence of carbohydrates, RegIIA had more close contacts with the binding site, especially with the C-loop (Fig. 5B). Therefore, we speculated that the presence of linear oligosaccharide chains did not only affect the binding mode of RegIIA at the h $\alpha 3\beta 4$ nAChR binding pocket, but also had a slight impact on C-loop conformation.

Effect of RegIIA H14 analogues at h $\alpha 3\beta 4$ nAChRs

Through MD simulations, we proposed that H14 of RegIIA played a vital role in interactions with the carbohydrate at $\beta 4$ N117. Thus, to explore H14 contribution to RegIIA activity at the h $\alpha 3\beta 4$ subtype, H14 RegIIA analogues were synthesized and tested at heterologous h $\alpha 3\beta 4$ nAChRs expressed in *Xenopus laevis* oocytes.

Due to the close contact between H14 and the carbohydrate at $\beta 4$ N117, residues with varied physico-chemical properties, such as hydrophilic or aromatic residues were introduced to position 14 of RegIIA. All analogues had substantially decreased potency in comparison to the wild-type RegIIA (Fig. 6A). Therefore, we speculated that the function of H14 may be unique. In addition to direct interactions with the carbohydrate, H14 might also play an essential role at sustaining the conformation of the peptide. Indeed, in MD simulations, the side chain of H14 formed an intraresidue H-bond (Fig. 6B, Supplementary Fig. S4), which contributes to maintaining the three-dimensional structure of RegIIA. Through circular dichroism analysis, we also identified that H14 is essential to the secondary structure of the peptide, and replacement of H14 resulted in certain degree of shift at 200–220 nmol/L (Fig. 6C).

In consideration of the direct interactions between the carbohydrate and H14, removal of the carbohydrate from $\beta 4$ N117 might explain decrease the potency of RegIIA. Indeed, in our previous study RegIIA was sixfold less potent at the $\beta 4$ N117D mutant (Cuny et al. 2016). However, the significant activity decrease was not likely resulted from $\beta 4$ N117 direct interactions due to the long distance between $\beta 4$ N117 and RegIIA H14. Thus, it is reasonable to deduce that the decrease is more likely due to the removal of the

Name	Sequence			
	I	II	III	IV
RegIIA	G	C	C	S
RegIIA [H14Y]	G	C	C	S
RegIIA [H14S]	G	C	C	S
RegIIA [H14D]	G	C	C	S
RegIIA [H14N]	G	C	C	S
RegIIA [H14W]	G	C	C	S
	P	A	C	N
	V	N	N	P
	H	I	C	*

Fig. 2 Amino acid sequence of α -Ctx RegIIA and H14 analogues. Residues at 14 position are colored red, and the disulfide bonds are colored blue. RegIIA and its derivatives contain two disulfide bonds (I–III and II–IV) (*represents amidated C-terminus)

carbohydrate rather than from the change of the side chain interactions with the toxin.

Conclusions

This study explored the effect of oligosaccharide chains on the binding mode of RegIIA at $\alpha 3\beta 4$ nAChRs, and the mutational effects at position 14 of RegIIA on the inhibitory activity of the peptide at $\alpha 3\beta 4$ nAChRs. The oligosaccharide chains interacted with N12 and N14 of RegIIA through unstable hydrogen bond interactions due to the flexibility of the sugar chain itself. Subsequent research suggested that the oligosaccharide chains also affected C-loop opening by inducing the C-loop to move inwards, thus reducing the opening. From electrophysiology experiments on heterologous $\alpha 3\beta 4$ nAChRs, we proposed the functional uniqueness

of H14 and its importance for the inhibitory activity of the peptide at $\alpha 3\beta 4$ nAChRs. Overall, this study further clarifies the structure–activity relationship of α -Ctx RegIIA, and provides important experimental and theoretical basis for the development of new peptide drugs.

Materials and methods

Homology modeling

An initial model of the complex of RegIIA and $\alpha 3\beta 4$ nAChRs was established using Modeller (Sali and Blundell 1993; Webb and Sali 2017) (version 9.14), as described previously (Yu et al. 2011). The crystal structure of acetylcholine binding protein (AChBP) bound with an α -Ctx PnIA mutant (PDB identifier 2BR8 (Celie et al. 2005)) and the crystal structure of $\alpha 3\beta 4$ nAChRs (PDB identifier 6PV7) were used as templates to construct α -Ctx RegIIA and $\alpha 3\beta 4$ nAChRs complex model. The $\alpha 3\beta 4$ nAChR model was composed of two $\alpha 3$ and three $\beta 4$ subunits. Modeller was used to generate 100 model structures, and those with the lowest DOPE score according to the energy score, were used for subsequent MD simulations to further optimize the structure. For the carbohydrate-apo model, the entire $\alpha 3\beta 4$ nAChR was simulated and for the carbohydrate-bound model only the ECD was simulated. Then, Na^+ was added to the whole system to make it appear electrically neutral and energy optimization of the whole system was carried out. First, constrained optimization was performed in solute constraining force of 100 kcal mol⁻¹Å, followed by 2000-step steepest descent method optimization and 3000-step conjugate gradient method optimization. After the first round of optimization, the position restriction was removed. The MD simulations process consisted of heating and equilibrium. The entire system was heated for 100 ps under equal

Fig. 3 Binding modes of RegIIA at the binding site of $\alpha 3\beta 4$ nAChR. **A** In the carbohydrate-free model, several hydrogen bonds (dashed lines) are formed between pairs of interacting residues. The $\alpha 3(+)$ interface is shown in cyan, $\beta 4(-)$ in purple, and RegIIA in silver. **B** In the glycoprotein model, the interaction mode is similar to the carbohydrate-free model, except that β -D-mannose forms hydrogen bonds with N12 and H14 (dashed lines). The $\alpha 3(+)$ interface is shown in peach, $\beta 4(-)$ in purple, and RegIIA in silver. Residues from the receptor and RegIIA are labeled using normal and italic fonts, respectively. The key interaction sites responsible for the binding of RegIIA are highlighted with dotted circles. **C–H**, magnification of the key sites in carbohydrate-free model (**C–E**) and glycoprotein model (**F–H**) highlighted with circles in (**A, B**)




Table 1 Pairwise interactions between the RegIIA and the $\alpha 3\beta 4$ nAChR

Residue ^a	Absence of oligosaccharide chain		Presence of oligosaccharide chain	
	+ ^b	- ^c	+ ^b	- ^c
S4	-	D173	K145	W59, D173
H5	Y93, S148, G147, Y190, Y197, <u>P198</u>	-	Y93, S148, D199, Y190, Y197, <u>P198</u>	W59
P6	S148, G147, W149	W59, L123	Y93, S148, W149	W59, L123
A7	S148, W149, Y197, S150, Y151	R83	Y93, S148, W149 Y197, S150, Y151	-
N9	-	<u>K61</u> , W59, L123	-	<u>K61</u> , W59, L123
V10	W149, S150	N111, I113, L121, W122, L123	W149, S150	K61, I113, L121, W122, L123
N11	<u>S150</u> , Y197	<u>R83</u> , I113, L121	<u>S150</u> , Y197	<u>R83</u> , L121, R115
N12	C193, E195, Y197	-	C193, Y197	<u>K61</u> , BMA
H14	-	-	-	BMA , NAG
I15	C192, C193	-	C192, C193	BMA

BMA and NAG oligosaccharides are in bold

^aResidues of RegIIA forming direct contact with the $\alpha 3\beta 4$ nAChR are listed. Contacts between $\alpha 3\beta 4$ nAChR and RegIIA are defined as van der Waals interactions when the distance between heavy atoms of RegIIA and $\alpha 3\beta 4$ nAChR is less than 4 Å. Residues of the $\alpha 3\beta 4$ nAChR and oligosaccharides forming hydrogen bonds with RegIIA are underlined

^bResidues from the principal subunit

^cResidues from the complementary subunit

volume conditions to gradually heat the temperature from 50 to 300 K, and the solute binding force was 5 kcal mol⁻¹.Å⁻². Subsequently, the MD simulation was performed for 250 ns under the boundary conditions of temperature and pressure maintained at 300 K and 1 atmosphere respectively (Supplementary Fig. S5).

In all dynamic simulations, Lipid14 force field (Dickson et al. 2014) was used for lipids, and ff14SB force field (Maier et al. 2015) was used for proteins and peptides. The SHAKE algorithm (Ryckaert et al. 1977) was used for hydrogen bonds where, the experimental step length in the heating process and the equilibrium process was set to 2 fs, and the PME (Darden et al. 1993) method was used to handle long-distance electrostatic interactions. The software VMD (Humphrey et al. 1996) (<http://www.ks.uiuc.edu/>) was used to analyze the motion trajectory after MD simulations and calculate the RMSD value of the resulting conformation.

Synthesis of α -conotoxin RegIIA and its analogues

The chemical synthesis of peptides was as previously reported (Yu et al. 2013). Rink amide resin (loading amount 0.631 mmol/g), was saturated with a mixed solution of dimethylformamide (DMF): dichloromethane (DCM) (1:1) for 4 h, then 20% piperidine solution was used to remove the Fmoc protecting group on the resin (30 min). Coupling was carried out with five times equivalent of amino acid and 4.5

times equivalent of HCTU dissolved in appropriate amount of DMF, then 5 times equivalent of diisopropylethylamine (DIPEA) were added. Reaction was carried out at a constant temperature in a shaker for 1 h, and washed three times with DCM and DMF. The Fmoc protective group was removed with 20% piperidine solution (30 min), washed three times with DCM and DMF followed with addition of 10 ml trifluoroacetic acid: triisopropylsilane: water (9:0.5:0.5) and reacted at a constant temperature on a shaker for 3 h. The resin was washed with DCM three times, and the filtrate was combined. After removal of excess trifluoroacetic acid, four times the volume of ice ether was added to precipitate the peptide, the suspension was centrifuged for 10 min, and the supernatant was discarded to obtain a white paste-like precipitate as a crude peptide. An appropriate amount of acetonitrile:water (1:1) was used to dissolve the crude peptide, and ammonium bicarbonate was added to pH = 8. The solution was oxidized for 48 h. The oxidized product was purified by RP (reversed-phase) HPLC using a gradient of buffer A (90% water, 10% acetonitrile, 0.05% trifluoroacetic acid) and B (90% acetonitrile, 10% water, 0.05% trifluoroacetic acid) of 100% to 40% for 1 h with a flow rate 6 ml/min. Peptide was oxidized by adding 5 mg/ml iodoacetonitrile, under closed environment at 28 °C for about 2 h. Subsequently, 5 mg/ml ascorbic acid aqueous solution was added to neutralize excess iodine. The completely oxidized product was separated and purified by RP-HPLC, and the




Fig. 4 The distance between RegIIA H14 and β -D-mannose (at β 4-N117 position), and β -D-glucosamine (at β 4-N117 position) during MD simulations. **A** Change of the distance between the ND1 of H14 and the O2 of β -D-mannose (cyan). During 150–200 ns, the average distance between two heavy atoms is 2.5 Å, suggesting a direct contact between β -D-mannose and H14 during this period. **B** Change of distance between O3 of β -D-glucosamine and NE of H14 (orange). Before 150 ns, the interaction between β -D-glucosamine and H14 was via van der Waals force

separation conditions were same as above. After the solution was lyophilized, a white powdery solid was obtained as the final product, and the product was frozen and stored at $-20\text{ }^{\circ}\text{C}$.

Circular dichroism

Circular dichroism (CD) was used to qualitatively judge the secondary structure of the peptide. The peptide was dissolved in an aqueous solution of acetonitrile (acetonitrile: water = 1:1). CD was performed on a Jasco J-810 spectrophotometer at room temperature over the wavelength range of 250–190 nm using an optical path of 1.0 mm, a bandwidth of 1.0 nm, and a response time of 2 s. Then the values were averaged from three scans. Finally, the formula $[\theta] = 1000 \cdot m \text{ deg} / (l \cdot c)$ was used to calculate the molar ellipticity $[\theta]$ of the peptide, where $m \text{ deg}$ is the raw CD data, c is the peptide molar concentration (mmol/L), and l is the cell path length (mm).





Fig. 5 Effects of the carbohydrate at α 3 N141 on the conformation of the binding site. **A** H186 of α 3 forms hydrogen bonds with β -D-glucosamine and α -D-mannose on the oligosaccharide chain. The α 3 interface is shown in peach, β 4 in purple, and oligosaccharide chain in silver white. **B** Superimposition of carbohydrate-free model (α 3 interface is shown in cyan and β 4 in purple) and glycoprotein model (α 3 interface is shown in peach and β 4 in purple). The distance used to characterize C-loop opening in the α 3 β 4 nAChR is measured between the CA of α 3 C193 and the CA of β 4 S40. The red and blue dashed lines indicate the distance of C-loop opening in the glycoprotein model and the carbohydrate-free model, respectively. **C** The 250 ns MD simulation of carbohydrate-free (red) and -bound (black) models showing change of the distance between the CA of α 3 C193 and the CA of β 4 S40

Xenopus laevis oocyte preparation and microinjection

Oocytes (Stage V–VI Dumont's classification; 1200–1300 μm in diameter) were removed from *X. laevis* by surgical laparotomy and defolliculated with 1.5 mg/ml collagenase Type II (Worthington Biochemical Corp., Lakewood, NJ, USA). Defolliculation was done at room temperature ($21\text{--}24\text{ }^{\circ}\text{C}$) for 1–2 h in OR-2 solution containing (in mmol/L) 82.5 NaCl, 2 KCl, 1 MgCl_2 , 5 HEPES, pH 7.4.

Plasmid pT7TS constructs of α 3 and β 4 were linearized with XbaI (NEB, Ipswich, MA, USA) for in vitro T7 message mMachine[®]-cRNA transcription (AMBION, Foster City, CA, USA). Oocytes were injected with 5 ng of α 3 β 4 cRNAs at α 3 to β 4 ratio of 1:1 (concentration confirmed spectrophotometrically and by gel electrophoresis) using glass pipettes as described previously (Arias et al. 2020).

Fig. 6 Mutational effects at the activity of RegIIA. **A** Bar graph of RegIIA and analogues (50 nmol/L) inhibition of ACh-evoked peak current amplitude mediated by $\alpha 3\beta 4$ nAChRs ($*P < 0.0001$ compared to RegIIA). Whole-cell currents were activated by 300 $\mu\text{mol/L}$ ACh (mean \pm SEM, $n = 6\text{--}12$). **B** The 250 ns MD simulation showing change of the distance between the N of H14 and the ND1 of H14 (green). The average distance between two heavy atoms is 3.5 \AA . **C** Circular dichroism spectra of RegIIA and its analogues



Two-electrode voltage clamp recording of oocytes and data analysis

Two-electrode voltage clamp recordings of *X. laevis* oocytes expressing $\alpha 3\beta 4$ nAChRs were performed 2–7 days post-cRNA microinjection at room temperature using a GeneClamp 500B amplifier and pClamp9 software interface (Molecular Devices, Sunnyvale, CA, USA) at a holding potential -80 mV. Both voltage-recording and current-injecting electrodes were pulled from GC150T-7.5 borosilicate glass (Harvard Apparatus, Holliston, MA, USA) and gave resistances of 0.3–1 M Ω when filled with 3 mol/L KCl.

Oocytes were perfused with ND96 solution (2 ml/min), followed by three ACh applications at 300 $\mu\text{mol/L}$ (half-maximal effective concentration for $\alpha 3\beta 4$ nAChR, Cuny et al. 2016) and 3-min washouts between applications. Perfusion was stopped, and oocytes were incubated with peptide for 5 min, followed by ACh plus peptide co-application with flowing ND96 solution. All peptides were tested at 50 nmol/L, close to the reported IC_{50} of wild-type RegIIA at $\alpha 3\beta 4$ nAChRs (Cuny et al. 2016). Peptide solutions were prepared in ND96 + 0.1% FBS. Oocytes were incubated with 0.1% FBS to ensure that the FBS and the pressure of the perfusion system had no effect on the nAChRs.

Pre and post peptide incubation peak current amplitudes were measured using Clampfit 10.7 software (Molecular Devices, Sunnyvale, CA, USA) and the relative current amplitude ($I_{\text{ACh+peptide}}/I_{\text{ACh}}$) was used to assess the activity of peptide at $\alpha 3\beta 4$ nAChRs. Results were analyzed by unpaired Student's *t* tests (GraphPad Prism 9 Software, La Jolla, CA, USA) and values of $P \leq 0.05$ were considered statistically significant.

Supplementary Information The online version contains supplementary material available at <https://doi.org/10.1007/s42995-021-00108-9>.

Acknowledgements This work was supported by the National Key Research and Development Program (2019YFC0312601), the grant from the Fundamental Research Funds for the Central Universities (201762011 and 201941012), National Natural Science Foundation of China (NSFC) (No. 81502977 and 41830535), and an Australian Research Council (ARC) Discovery Project Grant (DP150103990 awarded to Prof D.J. Adams). We thank Prof Adams for facilities and support of the functional studies carried out in *Xenopus* oocytes at IHMRI, University of Wollongong.

Author contributions RY conceived the project. RY, H-ST and TJ designed the experiments. MZ, H-ST and LX carried out the experiments. RY, H-ST and MZ analyzed the data. MZ wrote the manuscript draft. RY and H-ST revised the manuscript. All the authors have read and approved the submission for publication.

Declarations

Conflict of interests The authors declare that they have no conflict of interest.

Animal and human rights statement All experiment on animals were approved by the University of Wollongong and University of Sydney Animal Ethics Committees.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will

need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

References

- Arias HR, Tae HS, Micheli L, Yousuf A, Ghelardini C, Adams DJ, Di Cesare ML (2020) Coronaridine congeners decrease neuropathic pain in mice and inhibit $\alpha 9\alpha 10$ nicotinic acetylcholine receptors and CaV2.2 channels. *Neuropharmacology* 175:108194
- Azam L, McIntosh JM (2009) Alpha-conotoxins as pharmacological probes of nicotinic acetylcholine receptors. *Acta Pharmacol Sin* 30:771–783
- Case DA, Cheatham TE 3rd, Darden T, Gohlke H, Luo R, Merz KM Jr, Onufriev A, Simmerling C, Wang B, Woods RJ (2005) The Amber biomolecular simulation programs. *J Comput Chem* 26:1668–1688
- Celie PH, Kasheverov IE, Mordvintsev DY, Hogg RC, van Nierop P, van Elk R, van Rossum-Fikkert SE, Zhmak MN, Bertrand D, Tsetlin V, Sixma TK, Smit AB (2005) Crystal structure of nicotinic acetylcholine receptor homolog AChBP in complex with an α -conotoxin PnIA variant. *Nat Struct Mol Biol* 12:582–588
- Changeux JP (2012) The nicotinic acetylcholine receptor: the founding father of the pentameric ligand-gated ion channel superfamily. *J Biol Chem* 287:40207–40215
- Cuny H, Kompella SN, Tae HS, Yu R, Adams DJ (2016) Key structural determinants in the agonist binding loops of human $\beta 2$ and $\beta 4$ nicotinic acetylcholine receptor subunits contribute to $\alpha 3\beta 4$ subtype selectivity of α -Conotoxins. *J Biol Chem* 291:23779–23792
- Darden T, York D, Pedersen L (1993) Particle mesh Ewald: An N-log(N) method for Ewald sums in large systems. *J Chem Phys* 98:10089
- Dickson CJ, Madej BD, Skjevik AA, Betz RM, Teigen K, Gould IR, Walker RC (2014) Lipid14: The Amber lipid force field. *J Chem Theory Comput* 10:865–879
- Franco A, Kompella SN, Akondi KB, Melaun C, Daly NL, Luetje CW, Alewood PF, Craik DJ, Adams DJ, Mari F (2012) RegIIA: an $\alpha 4/7$ -conotoxin from the venom of *Conus regius* that potently blocks $\alpha 3\beta 4$ nAChRs. *Biochem Pharmacol* 83:419–426
- Gharpure A, Teng J, Zhuang Y, Noviello CM, Walsh RM Jr, Cabuco R, Howard RJ, Zaveri NT, Lindahl E, Hibbs RE (2019) Agonist selectivity and iIon permeation in the $\alpha 3\beta 4$ ganglionic nicotinic receptor. *Neuron* 104:501–511
- Glick SD, Sell EM, Maisonneuve IM (2008) Brain regions mediating $\alpha 3\beta 4$ nicotinic antagonist effects of 18-MC on methamphetamine and sucrose self-administration. *Eur J Pharmacol* 599:91–95
- Gotti C, Clementi F (2004) Neuronal nicotinic receptors: from structure to pathology. *Prog Neurobiol* 74:363–396
- Gotti C, Moretti M, Gaimarri A, Zanardi A, Clementi F, Zoli M (2007) Heterogeneity and complexity of native brain nicotinic receptors. *Biochem Pharmacol* 74:1102–1111
- Humphrey W, Dalke A, Schulten K (1996) VMD: visual molecular dynamics. *J Mol Graph* 14:27–28
- Jackson KJ, Sanjakdar SS, Muldoon PP, McIntosh JM, Damaj MI (2013) The $\alpha 3\beta 4^*$ nicotinic acetylcholine receptor subtype mediates nicotine reward and physical nicotine withdrawal signs independently of the $\alpha 5$ subunit in the mouse. *Neuropharmacology* 70:228–235
- Jackson KJ, Muldoon PP, De BM, Damaj MI (2015) New mechanisms and perspectives in nicotine withdrawal. *Neuropharmacology* 96:223–234
- Kompella SN, Cuny H, Hung A, Adams DJ (2015a) Molecular basis for differential sensitivity of α -conotoxin RegIIA at rat and human neuronal nicotinic acetylcholine receptors. *Mol Pharmacol* 88:993–1001
- Kompella SN, Hung A, Clark RJ, Mari F, Adams DJ (2015b) Alanine scan of α -conotoxin RegIIA reveals a selective $\alpha 3\beta 4$ nicotinic acetylcholine receptor antagonist. *J Biol Chem* 290:1039–1048
- Lebbe EK, Peigneur S, Wijesekara I, Tytgat J (2014) Conotoxins targeting nicotinic acetylcholine receptors: an overview. *Mar Drugs* 12:2970–3004
- Maier JA, Martinez C, Kasavajhala K, Wickstrom L, Hauser KE, Simmerling C (2015) ff14SB: Improving the accuracy of protein side chain and backbone parameters from ff99SB. *J Chem Theory Comput* 11:3696–3713
- Olivera BM (2006) *Conus* peptides: biodiversity-based discovery and exogenomics. *J Biol Chem* 281:31173–31177
- Olivera BM, Quik M, Vincler M, McIntosh JM (2008) Subtype-selective conopeptides targeted to nicotinic receptors: Concerted discovery and biomedical applications. *Channels (austin)* 2:143–152
- Posadas I, Lopez-Hernandez B, Cena V (2013) Nicotinic receptors in neurodegeneration. *Curr Neuropharmacol* 11:298–314
- Qian J, Liu YQ, Sun ZH, Zhangsun DT, Luo SL (2019) Identification of nicotinic acetylcholine receptor subunits in different lung cancer cell lines and the inhibitory effect of α -conotoxin TxID on lung cancer cell growth. *Eur J Pharmacol* 865:172674
- Robinson SD, Norton RS (2014) Conotoxin gene superfamilies. *Mar Drugs* 12:6058–6101
- Ryckaert JP, Ciccotti G, Berendsen H (1977) Numerical integration of the cartesian equations of motion of a system with constraints: molecular dynamics of n-alkanes. *J Comput Phys* 23:327–341
- Sali A, Blundell TL (1993) Comparative protein modelling by satisfaction of spatial restraints. *J Mol Biol* 234:779–815
- Sharma G (2013) The dominant functional nicotinic receptor in progenitor cells in the rostral migratory stream is the $\alpha 3\beta 4$ subtype. *J Neurophysiol* 109:867–872
- Taly A, Corringier PJ, Guedin D, Lestage P, Changeux JP (2009) Nicotinic receptors: allosteric transitions and therapeutic targets in the nervous system. *Nat Rev Drug Discov* 8:733–750
- Webb B, Sali A (2017) Protein structure modeling with MODELLER methods. *Mol Biol* 1654:39–54
- Xu Q, Tae HS, Wang Z, Jiang T, Adams DJ, Yu R (2020) Rational design of α -Conotoxin RegIIA analogues selectively inhibiting the human $\alpha 3\beta 2$ nicotinic acetylcholine receptor through computational scanning. *ACS Chem Neurosci* 11:2804–2811
- Yi X, Li W, Wang Y, Chen X, Ye F, Sun G, Chen J (2012) The relationship between CHRNA5/A3/B4 gene cluster polymorphisms and lung cancer risk: An updated meta-analysis and systematic review. *Medicine (baltimore)* 100:e24355
- Yu R, Craik DJ, Kaas Q (2011) Blockade of neuronal $\alpha 7$ -nAChR by α -conotoxin ImI explained by computational scanning and energy calculations. *PLoS Comput Biol* 7:e1002011
- Yu R, Kompella SN, Adams DJ, Craik DJ, Kaas Q (2013) Determination of the α -conotoxin Vc11 binding site on the $\alpha 9\alpha 10$ nicotinic acetylcholine receptor. *J Med Chem* 56:3557–3567
- Yu R, Tae HS, Xu Q, Craik DJ, Adams DJ, Jiang T, Kaas Q (2019) Molecular dynamics simulations of dihydro- β -erythroidine bound to the human $\alpha 4\beta 2$ nicotinic acetylcholine receptor. *Br J Pharmacol* 176:2750–2763